Results 51 to 60 of about 92,350 (272)

Secondary Infection and Co-infection in COVID-19 Patients Receiving Tocilizumab [PDF]

open access: yes
Objective: Tocilizumab (TCZ) is a recombinant humanized anti-IL-6 receptor monoclonal antibody that is beneficial in critically ill COVID-19 patients. However, the clinical efficacy and safety of immunosuppressants (including tocilizumab, sarilumab and ...
Hülya Sungurtekin   +3 more
core   +1 more source

Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab [PDF]

open access: yes, 2017
HS628 has been developed as a proposed biosimilar product of originator tocilizumab (Actemra®). An extensive physicochemical and biological characterization was conducted to assess similarity between HS628 and originator tocilizumab.
Shiwei Miao   +6 more
core   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.

open access: yesPLoS ONE, 2020
Tocilizumab is a humanized monoclonal antibody that is approved for the treatment of different human inflammatory diseases, including rheumatoid arthritis and cytokine release syndrome.
Juliane Lokau   +7 more
doaj   +1 more source

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial [PDF]

open access: yes, 2022
RATIONALE: Tocilizumab, an anti-interleukin-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic sclerosis-associated interstitial lung disease in a phase
Khanna, D   +10 more
core   +1 more source

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages

open access: yesInternational Journal of Infectious Diseases, 2023
Objectives: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world data,
Maaike C. Swets   +12 more
doaj   +1 more source

The Comprehensive Live Cell‐Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a devastating neurological disease that lacks serological biomarkers that can accurately reflect disease activity. We established a live cell‐based assay (LCBA) using serum with endogenous complement to quantify the overall cytotoxicity, offering a novel functional tool for monitoring
Xiaona Xu   +10 more
wiley   +1 more source

Tocilizumab combined with methotrexate versus single DMARD (methotrexate): The effect of tocilizumab is significant (Z = 4.70).

open access: yes, 2014
Tocilizumab combined with methotrexate versus single DMARD (methotrexate): The effect of tocilizumab is significant (Z = 4.70).
Thorbjørn Hubeck-Graudal (632411)   +4 more
core   +1 more source

Copine‐4 Paraneoplastic Autoimmune Encephalitis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT We characterize copine‐4 (CPNE4)‐IgG and report clinical associations. Among 844 samples with unclassified neural IgGs identified by mouse‐brain indirect immunofluorescence assay over 2 years, 5 samples (serum, 3; CSF, 2) from 3 patients produced a distinctive cerebrum‐restricted synaptic pattern.
Mimi S. Fang   +12 more
wiley   +1 more source

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions

open access: yes, 2011
Mahmud Mahamid1,3, Reuven Mader4, Rifaat Safadi1,2 1Liver Unit, Holy Family Hospital, Nazareth, Israel; 2Hadassah Medical Center, Jerusalem, Israel; 3Shaare Zedek Medical Center, Jerusalem, Israel; 4Rheumatology Unit, Ha’emek Medical Center ...
Safadi R   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy